Thai Q Nguyen et al., 2025-07-31: Nguyen et al. report that oral fenbendazole at 40 mg/kg combined with diisopropylamine dichloroacetate inhibits A549 lung cancer xenograft growth synergistically in nude mice.
Combining oral treatment of 100 mg/kg DADA and 40 mg/kg FZ synergistically inhibited tumor growth in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells.
Thai Q Nguyen et al., 2025-07-31: Nguyen et al. report that oral fenbendazole at 40 mg/kg combined with diisopropylamine dichloroacetate inhibits A549 lung cancer xenograft growth synergistically in nude mice. Study type: A549 human lung cancer xenograft in immunodeficient BALB/c nude mice, 66 tumour-bearing mice randomised into 7 groups plus a 6-mouse healthy control. Country: Vietnam (University of Science and Technology of Hanoi). Dose: FZ 40 mg/kg orally daily, alone and with DADA 20 or 100 mg/kg, from a tumour volume of 50 mm3 to day 60 of the experiment. Funder: 'All authors report that the project was funded by Thai Minh Pharmaceuticals JSC, Hanoi, Vietnam' (declared in the ICMJE disclosure form) – a pharmaceutical company funding, recorded here as neutral disclosure. Declared conflicts: 'The authors have no other conflicts of interest to declare.' Comparator: untreated tumour controls and cisplatin 5 mg/kg daily as positive control. This is the only lung cancer animal study in the record. Note that the same company funds and co-authors the group's companion cell-culture papers. Study type: animal.
